Comments on Li H et al. “A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma”
With great interest, we read the article “A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma” (by Li H et al.). This article suggests that high expression of matrix metalloproteinase 9 (MMP-9) is associated with a poor prognosis for patients with osteosarcoma . The result is encouraging. Nevertheless, some flaws existed in this meta-analysis that we would like to point out.
KeywordsMatrix metalloproteinase 9 Osteosarcoma Prognosis Meta-analysis
- 2.Huang Y, Wang JP. Expression of MMD2 and MMP-9 in osteosarcoma tissue and clinical significances [article in Chinese]. J Pract Oncol. 2009;23(1):35–7.Google Scholar
- 3.Luo XZ, Ni JD. Expression and clinical significance of MMP-9 and PCNA in osteosarcoma [article in Chinese]. J Clin Res. 2006;23(5):682–4.Google Scholar
- 4.Chen L, Lin JH, Zhang S. Expression of MMP-9 and TIMP-1 and their clinical significance in osteosarcoma [article in Chinese]. Chin J Exp Surg. 2004;21(12):1522–3.Google Scholar
- 5.Li WX, Ye ZM, Yang DS, Tao HM. The expression of vascular endothelial growth factor, matrix metalloproteinases 2,9 in osteosarcoma [article in Chinese]. Zhejiang Med J. 2006;28(9):691–4.Google Scholar